文献速递肿瘤 PET/CT核素与放射性配体治疗

神经内分泌肿瘤分子影像靶点:概述与更新

Targets for Molecular Imaging of Neuroendocrine Tumors (NETs): An Overview and Update.
PubMed 文献 · Semin Nucl Med · 2025-05-28

本综述概述神经内分泌肿瘤(NETs)分子影像靶点,重点阐述生长抑素受体显像在初始诊断、分期和治疗计划中的价值,提及[68Ga]Ga-DOTATATE和[68Ga]Ga-DOTA-LM3等高灵敏度和特异度示踪剂,并讨论葡萄糖代谢和成纤维细胞活化蛋白等非生长抑素受体靶点及双示踪剂方法的应用前景。

要点

  • 生长抑素受体显像在NETs初始诊断、分期和治疗计划中具有重要作用。
  • [68Ga]Ga-DOTATATE和[68Ga]Ga-DOTA-LM3等高灵敏度、高特异度示踪剂可准确界定病变范围。
  • 葡萄糖代谢和成纤维细胞活化蛋白等非生长抑素受体靶点可增强分子影像诊断能力。

核心结论

  • 分子影像尤其是PET和SPECT在NETs管理中起关键作用,生长抑素受体显像用于初始诊断、分期和治疗计划。
  • 非生长抑素受体靶点如葡萄糖代谢和成纤维细胞活化蛋白可增强分子影像诊断能力。
  • 双示踪剂等先进影像方法的整合有望优化治疗策略并改善患者结局。
  • 新型显像剂和技术的疗效与安全性需持续研究和临床试验验证。

研究设计与样本

  • 本文为综述,总结NETs分子影像靶点相关文献,未报告系统检索范围。

主要发现

  • [68Ga]Ga-DOTATATE和[68Ga]Ga-DOTA-LM3等高灵敏度、高特异度示踪剂可准确界定疾病范围并识别隐匿原发肿瘤。
  • 葡萄糖代谢和成纤维细胞活化蛋白等非生长抑素受体靶点可增强分子影像诊断能力。
  • 双示踪剂方法等先进影像模态的整合可能优化治疗策略并改善患者结局。

局限性

  • 原文指出新型显像剂和技术的疗效与安全性需持续研究和临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neuroendocrine neoplasms (NENs) represent a diverse group of tumors originating from neuroendocrine cells, characterized by their unique biological behavior and clinical manifestations. The incidence of neuroendocrine tumors (NETs) has been rising, necessitating effective diagnostic and therapeutic strategies. Molecular imaging, particularly through techniques such as PET and SPECT, plays a pivotal role in the management of NETs. This review highlights the significance of somatostatin receptor imaging in the initial diagnostic work-up, staging, and treatment planning for NETs, emphasizing the utility of radiopharmaceuticals like [68Ga]Ga-DOTATATE and [68Ga]Ga-DOTA-LM3. These agents demonstrate high sensitivity and specificity, allowing for accurate delineation of disease extent and identification of occult primary tumors. Furthermore, the review discusses the emerging role of nonsomatostatin receptor targets, such as glucose metabolism and fibroblast activation protein, in enhancing the diagnostic capabilities of molecular imaging. The integration of advanced imaging modalities, including dual-tracer approaches, is explored for their potential to refine therapeutic strategies and improve patient outcomes. As the field of molecular imaging continues to evolve, ongoing research and clinical trials are essential to validate the efficacy and safety of novel imaging agents and techniques, ultimately enhancing the management of patients with neuroendocrine tumors.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jafari E, Assadi M, Nasiri M, et al. Targets for Molecular Imaging of Neuroendocrine Tumors (NETs): An Overview and Update. Semin Nucl Med. 2025. PMID: 40441995. doi:10.1053/j.semnuclmed.2025.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。